The Latest Progress in the Application of Tofacitinib in Rheumatic Diseases--A Narrative Review.
- 1Department of Endocrinology, Heze Traditional Chinese Medicine Hospital Affiliated with Shandong University of Traditional Chinese Medicine, Heze, Shandong, People's Republic of China.
- 2Department of Pain Medicine, Shandong Provincial Hospital Heze Hospital (Heze Municipal Hospital), Heze, Shandong, People's Republic of China.
Abstract
Tofacitinib is an oral Janus kinase (JAK) inhibitor that modulates cytokine-dependent JAK/STAT signaling and has been extensively investigated in rheumatic diseases. This narrative review provides an updated synthesis of the pharmacological characteristics, mechanisms of action, clinical efficacy, safety, drug-drug interactions and dosing considerations of tofacitinib in special populations. The relevant literature published from January 2013 through December 2025 was identified through searches of MEDLINE, Embase, the Cochrane Library, and Google Scholar, supplemented by manual screening of reference lists. After screening and eligibility assessment, 89 clinical publications were included in the disease-specific evidence synthesis, and the strength of clinical evidence across disease indications was evaluated qualitatively. The most robust evidence is available for rheumatoid arthritis, with randomized trials, long-term extension studies, and real-world investigations demonstrating improvements in disease activity and physical function and inhibition of radiographic progression. Clinical evidence also supports therapeutic benefit in psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, whereas evidence for Takayasu arteritis, polymyalgia rheumatica, systemic lupus erythematosus, and anti-MDA5-positive dermatomyositis-associated interstitial lung disease remains limited or exploratory. Long-term integrated safety analyses in RA have reported incidence rates of serious adverse events of approximately 9.0-9.4 per 100 patient-years and serious infections of approximately 2.5-2.7 per 100 patient-years, while herpes zoster, major adverse cardiovascular events, venous thromboembolism, and malignancy remain clinically important safety considerations. Potential drug-drug interactions and dose adjustment in patients with renal or hepatic impairment and other special populations further require individualized assessment. Overall, tofacitinib has a well-established role in RA treatment and potential therapeutic value in several other rheumatic diseases; however, its use should be guided by disease-specific evidence, previous treatment exposure, comorbidities, concomitant medications, and individual safety risks. Further prospective and long-term studies are needed to better define its role in less well-established indications and special populations.
Related
- Physical and Rehabilitation Medicine Modalities in Pediatric Immune-Mediated Rheumatic Diseases: A Narrative Review of Current Evidence and Future Directions
- Cardiovascular Risk of Conventional Synthetic, Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Common Rheumatic Diseases: A Narrative Review of Current Evidence.
- Progress in the application of laser photocoagulation therapy in the treatment of pediatric retinal diseases.
- Towards a Novel Diagnostic Tool for Autoimmune Rheumatic Diseases: Classification of SLE Using FTIR Spectroscopy and Machine Learning
- COVID-19 severity and early inflammatory biomarkers in patients with immune-mediated inflammatory rheumatic diseases: a multicenter cohort study
BibTeX
@article{liu2026latest,
title = {{The Latest Progress in the Application of Tofacitinib in Rheumatic Diseases--A Narrative Review.}},
author = {Baocheng Liu and Qiyao Liu and Xuli Zhao},
journal = {Drug design, development and therapy},
year = {2026},
month = nov,
doi = {10.2147/dddt.s639406},
url = {https://europepmc.org/article/MED/42997327},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - The Latest Progress in the Application of Tofacitinib in Rheumatic Diseases--A Narrative Review.
AU - Baocheng Liu
AU - Qiyao Liu
AU - Xuli Zhao
PY - 2026
DA - 2026/11/02
JO - Drug design, development and therapy
DO - 10.2147/dddt.s639406
UR - https://europepmc.org/article/MED/42997327
AB - Tofacitinib is an oral Janus kinase (JAK) inhibitor that modulates cytokine-dependent JAK/STAT signaling and has been extensively investigated in rheumatic diseases. This narrative review provides an updated synthesis of the pharmacological characteristics, mechanisms of action, clinical efficacy, safety, drug-drug interactions and dosing considerations of tofacitinib in special populations. The relevant literature published from January 2013 through December 2025 was identified through searches of MEDLINE, Embase, the Cochrane Library, and Google Scholar, supplemented by manual screening of reference lists. After screening and eligibility assessment, 89 clinical publications were included in the disease-specific evidence synthesis, and the strength of clinical evidence across disease indications was evaluated qualitatively. The most robust evidence is available for rheumatoid arthritis, with randomized trials, long-term extension studies, and real-world investigations demonstrating improvements in disease activity and physical function and inhibition of radiographic progression. Clinical evidence also supports therapeutic benefit in psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, whereas evidence for Takayasu arteritis, polymyalgia rheumatica, systemic lupus erythematosus, and anti-MDA5-positive dermatomyositis-associated interstitial lung disease remains limited or exploratory. Long-term integrated safety analyses in RA have reported incidence rates of serious adverse events of approximately 9.0-9.4 per 100 patient-years and serious infections of approximately 2.5-2.7 per 100 patient-years, while herpes zoster, major adverse cardiovascular events, venous thromboembolism, and malignancy remain clinically important safety considerations. Potential drug-drug interactions and dose adjustment in patients with renal or hepatic impairment and other special populations further require individualized assessment. Overall, tofacitinib has a well-established role in RA treatment and potential therapeutic value in several other rheumatic diseases; however, its use should be guided by disease-specific evidence, previous treatment exposure, comorbidities, concomitant medications, and individual safety risks. Further prospective and long-term studies are needed to better define its role in less well-established indications and special populations.
SN - 1177-8881
ER -